Areteia Therapeutics Stock
HealthTechLooking to sell Areteia Therapeutics stock or options?
Eligible for:
Charitable Exchange Fund
Areteia Therapeutics is developing an oral medication aimed at treating eosinophilic asthma. Their platform concentrates on creating a drug that inhibits the maturation of eosinophils, potentially reducing inflammation and easing severe asthma symptoms. This approach could allow asthma patients to manage their condition more effectively, providing a more accessible option compared to injectable therapies.
Investors Include:
Viking Global Investors, Solas BioVentures, Maverick Capital, Saturn Partners, Bain Capital Life Sciences, Population Health Partners, GV, Marshall Wace, ARCH Venture Partners, Sanofi, Access Biotechnology.